ESTRO meets Asia 2024 - Abstract Book

S220

Interdisciplinary – Mixed sites/palliation

ESTRO meets Asia 2024

166

Digital Poster

Dose-escalated whole brain radiation therapy-simultaneous integrated boost in brain metastases

Julius Oentario 1 , Sri Mutya Sekarutami 1 , Reyhan Eddy Yunus 2 , Handoko Handoko 1 , Endang Nuryadi 1 , Soehartati Argadikoesoema Gondhowiardjo 1 1 Radiation Oncology, dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia. 2 Radiology, dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia

Purpose/Objective:

Explores the emerging approach of dose-escalated whole brain radiation therapy (WBRT) with simultaneous integrated boost (SIB) in managing brain metastases

Material/Methods:

Retrospective evaluation of seventeen patients with brain metastases treated with WBRT-SIB technique using two different treatment planning methods, heterogenous dose distribution or homogenous dose distribution, between January 2018 and January 2023

Results:

The study compromised 5 males (29.4%) and 12 females (70.6%). Nine patients (52.9%) with extensive brain metastasis lesion received heterogenous method (Group A), while the other 3 patients (17.7%) with extensive brain metastasis and 5 patients (29.4%) that had ≤ 4 lesion received homogenous method (Group B). Both groups receiving a total doses 36-50 Gy in 10-20 fractions. All treatments were completed without interuptions. Median follow-up for both groups were 7.1 months. Tumor respond with group A and group B methods was shown 66.7% and 75% complete/partial respond, respectively. there is no significant different within both methods. Median overall survival for group A was 9 months and group B was 6.5 months, respectively (p=0.913). 6-months intracranial control in Group A was higher as compared to Group B (66.67% vs 50%, p=0.029). There is no grade 3 or 4 toxicity was observe in both groups.

Figure 1. WBRT-SIB treatment planning. (A) heterogenous dose distribution SIB plan, (B) homogenous dose distribution SIB plan.